Electrophilic Quinazoline V-ATPase Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current V-ATPase inhibitors are either highly toxic to mammalian cells or lack defined mechanisms of inhibition, limiting their therapeutic potential for diseases such as cancer, renal, and bone diseases.
Innovation Solution
Development of a compound, Formula II, which targets the catalytic subunit of vacuolar H+ ATPase, specifically inhibiting its activity with a composition that includes electrophilic quinazolines, such as QZ1, that selectively binds to the V0 subunit c, providing potent and irreversible inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural product V-ATPase inhibitors (bafilomycin, archazolid, benzolactone enamides) are used, then potent inhibition of V-ATPase is achieved, but high toxicity to mammalian cells occurs
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of natural product inhibitors. Specifically, it develops synthetic analogs with altered molecular properties (electrophilic quinazoline structure with specific substituents R1-R6) that change the binding characteristics and reduce toxicity while maintaining V-ATPase inhibition potency. The IC50 values of synthesized compounds range from 10-100 nM, demonstrating maintained potency with improved safety profile.
Solution Approach 2:
The patent creates composite chemical structures by combining electrophilic quinazoline core with various substituent groups (alkyl, aryl, halogen, alkoxy, nitro, amino, hydroxyl groups at positions R1-R6). This composite approach allows optimization of both inhibitory activity and cellular toxicity profile by selecting appropriate combinations of substituents.
2Reliability
If synthetic V-ATPase inhibitors (RTA203, NiK12192, SB24278, TBTCl, 3-Br-PA) are used, then V-ATPase inhibition is achieved, but binding site and mechanism of inhibition remain undefined
Solution Approach 1:
The patent uses electrophilic quinazoline compounds as intermediaries to study V-ATPase binding. The compounds are designed with specific electrophilic groups that can form covalent or strong non-covalent interactions with nucleophilic residues in the binding pocket, allowing mechanistic studies. The defined structure-activity relationships provide information about the binding site location and interaction mechanism.
Solution Approach 2:
The patent segments the V-ATPase binding interface by designing compounds with specific functional groups that interact with different subunits. The electrophilic quinazoline structure can interact with both V1 and V0 domains, allowing dissection of binding mechanisms and identification of specific interaction sites through structure-activity relationship analysis.
3Reliability
If plecomacrolide inhibitors (bafilomycin, concanamycin) are used, then selective V-ATPase inhibition is achieved, but mitochondrial function is impaired due to potassium ionophore activity
Solution Approach 1:
The patent extracts the V-ATPase binding activity from plecomacrolide structures while removing the potassium ionophore functionality. The electrophilic quinazoline compounds are designed to specifically target V-ATPase through electrophilic-nucleophilic interactions, eliminating the off-target mitochondrial effects associated with plecomacrolides' ionophore activity.
Solution Approach 2:
The patent converts the electrophilic reactivity, which could be harmful, into a beneficial mechanism for specific V-ATPase targeting. The electrophilic groups form selective covalent or strong non-covalent bonds with nucleophilic residues in the V-ATPase binding site, providing irreversible or sustained inhibition without the harmful mitochondrial side effects of plecomacrolides.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively inhibits V-ATPase activity with an apparent IC50 value of 30 nM, demonstrating rapid and potent target engagement, reducing vesicle re-acidification and offering a safer therapeutic option for human diseases.
Implementation Method 1
electrophilic quinazolines, such as QZ1, that selectively binds to the V0 subunit c
Implementation Method 2
The V1 domain is composed of eight different subunits (A, B, C, D, E, F, G, H) and the V0 domain contains five different subunits (a, b, c, d, and e) in mammals, some of which are present in multiple copies. The core of the V1 domain contains a hexamer of A and B subunits, which participates in ATP binding and hydrolysis
Data Source
AI summary
A compound of Formula II,is provided. R1, R2 and R3 are independently either hydrogen, alkyl, aryl, halogen, alkoxy, nitro, amino or hydroxyl. X is either F, Cl, Br, I or CN. Y is either N or CH. Compositions that include Formula II can be used to inhibit vacuolar H+ ATPase.